Lipid-Encapsulated mRNAs Encoding Complex Fusion Proteins Potentiate Antitumor Immune Responses
Authors:
- Casey W. ShuptrineCSCasey W. Shuptrine
- Yuhui ChenYCYuhui Chen
- Jayalakshmi MiriyalaJMJayalakshmi Miriyala
- Karen LenzKLKaren Lenz
- Danielle MoffettDMDanielle Moffett
- Thuy-Ai NguyenTNThuy-Ai Nguyen
- Jenn MichauxJMJenn Michaux
- Kristen CampbellKCKristen Campbell
- Connor SmithCSConnor Smith
- Marc MorraMMMarc Morra
- Yisel Rivera-MolinaYRYisel Rivera-Molina
- Noah MurrNMNoah Murr
Open Access
- 21 February 2024
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 84 (10) , 1550-1559
Abstract
Lipid nanoparticle (LNP)–encapsulated mRNA has been used for in vivo production of several secreted protein classes, such as IgG, and has enabled the development of personalized vaccines in oncology. Establishing the feasibility of delivering complex multispecific modalities that require higher-order structures important for their function could help expand the use of mRNA/LNP biologic formulations. Here, we evaluated whether in vivo administration of mRNA/LNP formulations of SIRPα-Fc-CD40L and TIGIT-Fc-LIGHT could achieve oligomerization and extend exposure, on-target activity, and antitumor responses comparable with that of the corresponding recombinant fusion proteins. Intravenous infusion of the formulated LNP-encapsulated mRNAs led to rapid and sustained production of functional hexameric proteins in vivo, which increased the overall exposure relative to the recombinant protein controls by ∼28 to 140 fold over 96 hours. High concentrations of the mRNA-encoded proteins were also observed in secondary lymphoid organs and within implanted tumors, with protein concentrations in tumors up to 134-fold greater than with the recombinant protein controls 24 hours after treatment. In addition, SIRPα-Fc-CD40L and TIGIT-Fc-LIGHT mRNAs induced a greater increase in antigen-specific CD8+ T cells in the tumors. These mRNA/LNP formulations were well tolerated and led to a rapid increase in serum and intratumoral IL2, delayed tumor growth, extended survival, and outperformed the activities of benchmark mAb controls. Furthermore, the mRNA/LNPs demonstrated improved efficacy in combination with anti-PD-L1 relative to the recombinant fusion proteins. These data support the delivery of complex oligomeric biologics as mRNA/LNP formulations, where high therapeutic expression and exposure could translate into improved patient outcomes. Significance: Lipid nanoparticle–encapsulated mRNA can efficiently encode complex fusion proteins encompassing immune checkpoint blockers and costimulators that functionally oligomerize in vivo with extended pharmacokinetics and durable exposure to induce potent antitumor immunity.Keywords
All Related Versions
Funding Information
- Shattuck Labs, Inc.
- Moderna, Inc.
This publication has 27 references indexed in Scilit:
- CD40 Enhances Type I Interferon Responses Downstream of CD47 Blockade, Bridging Innate and Adaptive ImmunityCancer Immunology Research, 2020
- Intraperitoneal Route of Drug Administration: Should it Be Used in Experimental Animal Studies?Pharmaceutical Research, 2019
- Durable anticancer immunity from intratumoral administration of IL-23, IL-36γ, and OX40L mRNAsScience Translational Medicine, 2019
- Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapyJournal for ImmunoTherapy of Cancer, 2018
- A Novel Amino Lipid Series for mRNA Delivery: Improved Endosomal Escape and Sustained Pharmacology and Safety in Non-human PrimatesMolecular Therapy, 2018
- Chemokines in the cancer microenvironment and their relevance in cancer immunotherapyNature Reviews Immunology, 2017
- Improved anti-leukemia activities of adoptively transferred T cells expressing bispecific T-cell engager in miceBlood Cancer Journal, 2016
- Advances in recombinant antibody manufacturingApplied Microbiology and Biotechnology, 2016
- Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routesJournal of Controlled Release, 2015
- Clinical targeting of the TNF and TNFR superfamiliesNature Reviews Drug Discovery, 2013